FY2027 EPS Estimates for AbbVie Increased by Leerink Partnrs

AbbVie Inc. (NYSE:ABBV) – Equities research analysts at Leerink Partnrs lifted their FY2027 earnings per share (EPS) estimates for AbbVie in a research note issued on Wednesday, September 24th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $16.33 per share for the year, up from their prior estimate of $16.01. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Leerink Partnrs also issued estimates for AbbVie’s FY2028 earnings at $18.38 EPS and FY2029 earnings at $19.77 EPS.

A number of other equities analysts have also issued reports on the company. BMO Capital Markets raised their price target on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Daiwa America raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 7th. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and raised their price target for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Cantor Fitzgerald raised their price target on AbbVie from $215.00 to $245.00 and gave the stock an “overweight” rating in a report on Monday, September 15th. Finally, Guggenheim raised their price target on AbbVie from $216.00 to $227.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $223.45.

AbbVie Stock Performance

NYSE ABBV opened at $218.23 on Thursday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie has a 52-week low of $163.81 and a 52-week high of $225.16. The business’s 50-day moving average price is $205.61 and its 200 day moving average price is $195.22. The firm has a market cap of $385.52 billion, a P/E ratio of 103.92, a P/E/G ratio of 1.31 and a beta of 0.53.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.24 by ($0.27). AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.42 billion for the quarter, compared to analysts’ expectations of $14.93 billion. During the same period in the prior year, the business earned $2.65 EPS. The business’s quarterly revenue was up 6.6% compared to the same quarter last year.

Institutional Investors Weigh In On AbbVie

Several institutional investors have recently modified their holdings of the company. Sivia Capital Partners LLC raised its position in shares of AbbVie by 1.1% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company’s stock worth $848,000 after purchasing an additional 51 shares during the last quarter. FF Advisors LLC raised its position in shares of AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock worth $286,000 after purchasing an additional 53 shares during the last quarter. Landaas & Co. WI ADV raised its position in shares of AbbVie by 1.1% during the 2nd quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock worth $920,000 after purchasing an additional 53 shares during the last quarter. Bernardo Wealth Planning LLC raised its position in shares of AbbVie by 2.9% during the 2nd quarter. Bernardo Wealth Planning LLC now owns 1,909 shares of the company’s stock worth $354,000 after purchasing an additional 53 shares during the last quarter. Finally, Private Management Group Inc. raised its position in shares of AbbVie by 1.9% during the 1st quarter. Private Management Group Inc. now owns 2,938 shares of the company’s stock worth $616,000 after purchasing an additional 54 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Activity at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares of the company’s stock, valued at $35,178,278.64. The trade was a 19.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of the business’s stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the sale, the executive vice president directly owned 58,247 shares in the company, valued at $11,562,611.97. This trade represents a 18.58% decrease in their position. The disclosure for this sale can be found here. 0.25% of the stock is owned by insiders.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be paid a dividend of $1.64 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.0%. AbbVie’s payout ratio is 312.38%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.